

Main Conference - Preliminary PROGRAMME - July

Thursday, 7 May 2015

11:00-12:00	Press Conference	
12:00-13:00	Satellite Symposium 1	
13:00-13:15 15'	Official welcome	
5'	Welcome to the IMPAKT Conference	Co-Founders
10'	Introduction to the IMPAKT Conference	Chairs
13:15-14:15 60'	Opening Keynote session	Co-Chairs: To be defined
30'	Tracing the cellular origin of breast cancer	Cedric Blanpain, BE
20'	Clinical significance of the cellular origin of breast cancer Or Concepts on cells of origin of cancer: Implications for clinical practice	To be announced
10'	Q&A	
14:15-15:45 90'	Session 1 The molecular origin of breast cancer: Clinical significance of genomic patterns	Co-Chairs: To be defined
20'	Genomic ventures to explore tumour progression and intra-tumour heterogeneity in breast cancer	Peter van Loo, UK
20'	APOBEC and mutation signatures: Connecting immune response and breast cancer development or APOBEC mutation signatures and the origin of breast cancer	To be announced
15'	Which mutations are relevant? Strategies for identification	To be announced
15'	Therapeutic implications of mutational evolution in breast cancer	Lajos Pusztai, US
20'	Q&A / General Discussion	
15:45-16:15	Coffee break	
16:15-17:45 90'	Best abstracts session – Oral abstracts 6 x abstracts@10mins, 2 x Discussants@15' each incl. Q&A	Co-Chairs: Nick Turner, UK and Carsten Denkert, DE
10'	Abstract 1	
10'	Abstract 2	
10'	Abstract 3	
15'	Discussant Abstracts 1-3	
10'	Abstract 4	
10'	Abstract 5	
10'	Abstract 6	
15'	Discussant Abstracts 4-6	
17:45-19:00	Welcome reception and Poster Walk	

Friday, 8 May 2015

08:30-09:15 45'	Keynote lecture	Co-Chairs: To be defined
30'	Dissecting the proteome of breast cancer	Matt Ellis, US
15'	Q&A	
09:15-10:15 60'	Session 2 Mutations and therapy resistance: Impact of mutations in the clinic	Co-Chairs: To be defined
15'	ESR1 mutations and resistance to endocrine therapy	Sarat Chandarlapaty, US
15'	PIK3CA + HER2 mutations	Ian Krop, US
15'	Clinical relevance: How do we manage mutational mechanisms of resistance?	Sibylle Loibl, DE
15'	Q&A / General Discussion	
10:15-10:45	Coffee break	
10:45-12:15 90'	Session 3 Microenvironment and metastatic cascade in breast cancer	Co-Chairs: To be defined
20'	Tumour evolution in the metastatic setting	Christine Desmedt, BE
20'	The impact of tumour genetics on host immune response	To be announced
20'	Strategies to modulate the immune system in breast cancer: Checkpoint inhibitors and beyond	Karen Willard-Gallo, BE
15'	Clinical perspectives	Giuseppe Curigliano, IT
15'	Q&A / General Discussion	
12:15-13:15	<i>Satellite Symposium 2</i>	
13:15-13:45	Lunch	
13:45-15:15	<i>Satellite Symposium 3</i>	
15:15-15:30	Coffee Break	
15:30-17:35 125'	Session 4 Translational clinical trial approaches in early stage breast cancer	Co-Chairs: To be defined
20'	New aspects of molecular imaging in breast cancer	Elisabeth de Vries, NL
20'	If I would start the I-SPY trials again what would I do differently?	To be announced
20'	Selection criteria for post neoadjuvant therapy concepts	Gunter von Minckwitz, DE
20'	POETIC strategies: Optimising neo-adjuvant and window studies in oestrogen receptor positive breast cancer	Mitchell Dowsett, UK
45'	Panel discussion: Integration of neoadjuvant and adjuvant trials – do we need new strategies for early breast cancer?	To be announced
17:35-18.35 60'	Keynote Lecture 3	Co-Chairs: To be defined
30'	The impact of germline genetics on breast cancer risk and integration in clinical practice	Nazneen Rahman, UK
20'	Clinical interpretation	Judy Garber, US
10'	Q&A / General Discussion	

Saturday, 9 May 2015

09:00-10:00 60'	Session 5 – Debate Chemotherapy will have a trivial role in the future of precision medicine	Co-Chairs: To be defined
20'	Speaker Pro	David Cameron, UK
20'	Speaker Contra	Larry Norton, US
20'	Moderated discussion with audience	Lead by Fabrice André, FR
10:00-10:30	Coffee break	
10:30-10:45	Susan G. Komen for the Cure® award session	TBD
10:45-11:45 60'	Session 6 Triple negative breast cancer: First results from tackling the diversity	Co-Chairs: To be defined
15'	Genomic and morphological heterogeneity in TNBC	Jorge Reis-Filho, US
15'	Platinum and targeted therapy in TN breast cancer- for all patients or only a subset?	Andrew Tutt, UK
30'	Panel discussion: Potential resistance targets, recent study results and new trial concepts	Panellists: Jorge Reis-Filho, US Andrew Tutt, UK Nick Turner, UK + 2-4 among the invited speakers
11:45-12:00 15'	Closing remarks	Co-Chairs: Nick Turner, UK and Carsten Denkert, DE